Cite
Foster JH, Voss SD, Hall DC, et al. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021;27(13):3543-3548doi: 10.1158/1078-0432.CCR-20-4224.
Foster, J. H., Voss, S. D., Hall, D. C., Minard, C. G., Balis, F. M., Wilner, K., Berg, S. L., Fox, E., Adamson, P. C., Blaney, S. M., Weigel, B. J., & Mossé, Y. P. (2021). Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3543-3548. https://doi.org/10.1158/1078-0432.CCR-20-4224
Foster, Jennifer H, et al. "Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3543-3548. doi: https://doi.org/10.1158/1078-0432.CCR-20-4224
Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL, Fox E, Adamson PC, Blaney SM, Weigel BJ, Mossé YP. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 Jul 01;27(13):3543-3548. doi: 10.1158/1078-0432.CCR-20-4224. Epub 2021 Feb 10. PMID: 33568345; PMCID: PMC8254744.
Copy
Download .nbib